Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Therapeutic Solutions International, Inc. (OTC: TSOI).

Full DD Report for TSOI

You must become a subscriber to view this report.


Recent News from (OTC: TSOI)

Therapeutic Solutions International Completes Phase 1 Clinical Trial in Advanced Cancer Patients for Right to Try Access of its StemVacs Product for American Cancer Patients
Company to use Phase I Data of its Cancer Stem Cell Immunotherapy to Allow for use in the USA under President Donald Trump's  Right to Try Law OCEANSIDE, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions International, Inc., ( OTC Markets: TSOI ...
Source: GlobeNewswire
Date: September, 04 2018 09:00
Therapeutic Solutions International Recruits NFL Chargers Hall of Famer Wes Chandler to Lead NeuroStilbene for Chronic Traumatic Encephalopathy in Football Players
Company to Advance NeuroStilbene Product for High-Performance Athletes Susceptible to Head Injuries OCEANSIDE, Calif., Aug. 22, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions International, Inc., ( OTC Markets: TSOI ) announced today recruitment of Wes Chan...
Source: GlobeNewswire
Date: August, 22 2018 09:00
Therapeutic Solutions International Reports Synergistic Enhancement of Ozone Therapy Efficacy in Prostate, Breast and Ovarian Cancer Cells by Pterostilbene
Clinical Stage Cancer Immunotherapy Biotechnology Company Files Patent Expanding Uses of its Pterostilbene Based Product Pipeline OCEANSIDE, Calif., Aug. 13, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutic Solutions International, Inc., ( OTC Markets: TSOI ) announced today f...
Source: GlobeNewswire
Date: August, 13 2018 09:00
Therapeutic Solutions International Develops Microemulsion Formulation of Alpha Lipoic Acid for Intranasal Delivery
Company Expands Product Pipeline in Neurodegenerative Arena OCEANSIDE, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions International, Inc., ( OTC Markets: TSOI ) announced today successful production of a stable microemulsion of Alpha Lipoic Acid...
Source: GlobeNewswire
Date: August, 06 2018 09:00
Therapeutic Solutions International Recruits Internationally Recognized Cancer Immunotherapy Pioneer Dr. Francesco Marincola to Accelerate StemVacs and NanoStilbene Clinical Development
Company Focuses on Non-Toxic Therapies Using Immune System  to Selectively Kill Cancer Cells through Immunotherapy OCEANSIDE, Calif., July 23, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced the appointment of...
Source: GlobeNewswire
Date: July, 23 2018 09:00
Therapeutic Solutions International, Inc., Releases Intranasal Formulation of Pterostilbene for Rapid Access to Blood-Brain Barrier
Company Expands its Pterostilbene Based Portfolio into Brain Cancers OCEANSIDE, Calif., July 16, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced today the release of NeuroStilbene, a proprietary nano-formulation of pte...
Source: GlobeNewswire
Date: July, 16 2018 09:00
Therapeutic Solutions International, Inc., Appoints Juergen Winkler, MD, ABIHM to Scientific Advisory Board
Pioneer of Functional Medicine Teams Up with Clinical Stage Biotechnology Company in Commercialization of Non-Toxic Immunotherapy OCEANSIDE, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire --Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced today that J...
Source: GlobeNewswire
Date: July, 09 2018 09:00
Therapeutic Solutions International Announces Clinical Proof of Concept of Nanoparticle Pterostilbene Formulation: NanoStilbene(TM)
Early Clinical Trial Data Supports Enhanced Biodistribution of NanoStilbene ™ Compared to Standard Pterostilbene When Orally Administered OCEANSIDE, Calif., July 02, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announce...
Source: GlobeNewswire
Date: July, 02 2018 09:17
Therapeutic Solutions International Releases "IsoStilbene" Injectable Formulation of Pterostilbene Under Granted Patent for Augmentation of Immunotherapy and Targeting of Cancer Stem Cells
OCEANSIDE, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced today the formulation and initial clinical implementation of an injectable form of pterostilbene called "IsoStilbene derived from their '047 paten...
Source: GlobeNewswire
Date: June, 25 2018 09:00
Therapeutic Solutions International Announces the Appointment of James Veltmeyer, MD as Chief Medical Officer
OCEANSIDE, Calif., June 18, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Therapeutics Solutions International, Inc., (OTC Markets:TSOI) previously announced their plans to provide access to its clinical stage cancer immunotherapy product StemVacs under the Right To Try law signed by Presiden...
Source: GlobeNewswire
Date: June, 18 2018 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-070.00450.00360.0050.00321,175,310
2018-12-060.00370.00450.00570.00372,274,134
2018-12-050.00390.00320.00390.00321,539,700
2018-12-040.00390.00320.00390.00321,539,700
2018-12-030.00390.00330.00420.00331,772,921

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-07724,3991,175,31061.6347Short
2018-12-061,010,3872,274,13444.4295Short
2018-12-04564,5701,539,70036.6675Short
2018-12-03843,4741,772,92147.5754Short
2018-11-30792,22112,358,3696.4104Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on TSOI.


About Therapeutic Solutions International, Inc. (OTC: TSOI)

Logo for Therapeutic Solutions International, Inc. (OTC: TSOI)

Therapeutic Solutions International, Inc. is involved in the medical sciences market. We are focused on three different areas within the same market. They are outlined as follows: . Dietary Supplements . Immunotherapy, and . Fetal Maternal Health Our business plan is twofold: . Produce and refine current product lines and develop them further, and . To focus on leveraging immunological processes to diagnose and intervene in niche areas of unmet medical needs.

 

 

 

Current Management

  • Timothy G. Dixon / President, CEO
  • Gerry Berg / CFO, Corporate Secretary
  • Gerry Berg /
  • Timothy G. Dixon /
  • Thomas E. Ichim, Ph.D /

Current Share Structure

  • Market Cap: $5,080,956 - 03/12/2018
  • Authorized: 990,000,000 - 07/07/2017
  • Issue and Outstanding: 806,501,000 - 11/15/2017
  • Float: 46,317,028 - 07/07/2017

 


Recent Filings from (OTC: TSOI)

Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: May, 11 2018
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: May, 07 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: May, 07 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 17 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: March, 29 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 16 2017
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: November, 14 2017
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: October, 31 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 26 2017

 

 


Daily Technical Chart for (OTC: TSOI)

Daily Technical Chart for (OTC: TSOI)


Stay tuned for daily updates and more on (OTC: TSOI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: TSOI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in TSOI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of TSOI and does not buy, sell, or trade any shares of TSOI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/